← Back

Jenkem Technology Co Ltd

Jenkem Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medical and pharmaceutical polyethylene glycol (PEG), and its derivatives in China and internationally. The company offers high molecular weight polyethylene glycol derivatives comprising branched, methoxylated, bifunctionalized, heterofunctionalized disubstituted, multi-arm, multi-arm heterofunctional disubstituted, amino-polyglycolic, N-terminated polyethylene glycol-modified, and thiol-modified polyethylene glycol PEG products; monodisperse PEG products consisting of methoxy monodisperse PEG derivatives, and monodisperse PEG derivatives with the same functional and heterofunctional groups; click chemistry; lipid nanoparticles delivery system accessories; PEG linkers, such as ADC and PROTAC linkers; PEG medical devices, which include multi-arm PEG derivatives; polyethylene glycol standards; block copolymers; PEG standards; long-acting polypeptide fatty acid side chains, including semaglutide, tirzepatide/icodec, and somapacitan intermediates; and Silkrose injectable cross-linked sodium hyaluronate gel, a passive implantable device used to correct nasolabial folds through subcutaneous injection. It also provides technical services, such as development of synthetic methods, quality research and IND application, analytical method development, and polyethylene glycolization technology services. Jenkem Technology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.

Price · split & dividend adjusted
News & notes moving 688356.CG
Semiconductors▼

YMTC Holdings' STAR Market IPO application accepted, plans to raise 33 billion yuan

YMTC Holdings' application for an initial public offering and listing on the STAR Market has been accepted by the Shanghai Stock Exchange, with a planned fundraising amount of 33 billion yuan. The sponsors are CITIC Securities and China Securities. The prospectus shows that the company's profitability has improved rapidly since turning a profit in 2024. From January to March 2026, it achieved operating revenue of 47.042 billion yuan and net profit attributable to the parent company of 33.379 billion yuan. According to TrendForce data, during the same period, the company ranked third globally and first in China among NAND Flash manufacturers by both sales revenue and shipment volume. In addition, CanSino Biologics announced that it is developing mRNA preventive vaccines and therapeutic biological products. JenKem Technology clarified that it has not directly supplied LNP core raw materials to Moderna. Several other STAR Market companies, including Sinovac Biotech, Hwatsing Technology, and UCloud, disclosed their semi-annual results.
688356.CG ▼688185.CG
Semiconductors ▲
CLS·6dRead more ▾
Biotech & Genomic Medicine▲

Moderna shares surge nearly 180%, chemical pharmaceutical concept rallies strongly

On August 20, the chemical pharmaceutical concept rose 4.21% intraday, with JenKem Technology, Lummy Pharmaceutical, Youcare Pharmaceutical and other constituent stocks leading gains. In news, overnight US stock Moderna shares surged nearly 180%, as Merck and Moderna announced the first Phase III clinical trial of their jointly developed mRNA personalized cancer vaccine intismeran autogene achieved preliminary positive results. A China Merchants Securities research report noted that in 2026, the chemical pharmaceutical industry is in a gear-shift period of concentrated clearing of legacy risks and accelerated realization of innovation achievements. Leading companies, relying on technology platform upgrades, have entered late-stage clinical and early commercialization phases. It recommends focusing on differentiated leaders with complex formulation platforms and global business development capabilities.
MRNA ▲MRK ▲688356.CG ▲
Biotech & Genomic Medicine ▲
南方财经网·6dRead more ▾
© 2026 MarketDXAsset